A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)
Clinical trial NCT04933227 · TERMINATED
Trial details
- NCT number
- NCT04933227
- Sponsor
- Hoffmann-La Roche
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-08-06
- Primary completion
- 2023-11-17
- Enrollment
- 29
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.